Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2021
Event: Entry into material definitive agreements to form Oravax Medical Inc., a Delaware corporation focused on developing novel oral COVID-19 vaccines.
Key Financial Metrics and Transaction Terms
This filing details a strategic transaction rather than periodic financial results. Key financial terms include:
- Equity Investment: Oramed agreed to purchase 1,890,000 shares of Oravax common stock for an aggregate amount of $1.5 million, representing a 63% equity interest.
- Partner Contribution: Akers Biosciences Inc. agreed to contribute $1.5 million in cash and substantially all assets of Cystron Biotech LLC to Oravax.
- Royalties: Oramed will receive royalties equal to 7.5% on net sales of products commercialized by Oravax related to the licensed technology.
- Sublicensing Fees: Oramed will receive 15% of any non-sales-based consideration received by Oravax from permitted sublicensees.
- Milestone Payments: Oramed is eligible for payments ranging between $25 million and $100 million based on the achievement of certain sales milestones.
Note: The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for Oramed Pharmaceuticals Inc. for a specific reporting period.
Material Changes and Strategic Developments
The primary material change is the formation of Oravax Medical Inc. and the execution of two key agreements:
- License Agreement: Oramed granted Oravax an exclusive, worldwide license to use Oramed's proprietary POD oral delivery technology to develop, manufacture, and commercialize oral vaccines for COVID-19 and other novel coronaviruses using Premas Biotech's triple antigen virus-like particle technology.
- Stockholders Agreement: Established governance where Oramed appoints two of three board members (including the CEO as Chairman), while Akers retains the right to appoint one member for three years. Includes transfer restrictions and rights of first refusal for other stockholders.
Outlook, Management Commentary, and Risks
Scientific Progress and Timeline:
- Pilot Study Results: A pilot study in pigs showed that a single oral administration of the vaccine promoted systemic immunity (IgG) and mucosal immunity (IgA) within 42 days.
- Clinical Trial Outlook: Oravax anticipates commencing a clinical study in human subjects during the second quarter of 2021.
- Historic scientific results do not guarantee future trial outcomes.
- Risks include delays in clinical trials, regulatory approval, and patent protection.
- Competition from other pharmaceutical companies and the need for additional funding.
- Potential for laboratory results not to translate to real-world settings.
Investor Verification Checklist
- Verify the terms of the License Agreement (Exhibit 10.1) regarding the definition of "net sales" and specific sales milestones triggering the $25M-$100M payments.
- Confirm the status of the $1.5 million cash contributions from both Oramed and Akers to Oravax.
- Monitor the commencement of the human clinical study scheduled for Q2 2021.
- Review the full text of the Stockholders Agreement (Exhibit 10.2) for details on transfer restrictions and future financing participation rights.
- Assess the competitive landscape for oral COVID-19 vaccines and the regulatory pathway for the specific technology platform.